Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
Asciminib is a novel tyrosine kinase inhibitor (TKI) that specifically targets the myristoyl pocket.It has increased selectivity and potent activity against BCR-ABL1 and the mutants that most frequently prevent the activity of the ATPbinding competitive inhibitors.Results for clinical trials in patients with chronic myeloid leukemia that have recei